Literature DB >> 12429635

Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors.

Jaclyn A Biegel1, Lu Tan, Fan Zhang, Luanne Wainwright, Pierre Russo, Lucy B Rorke.   

Abstract

Germ-line and acquired mutations of the hSNF5/INI1 tumor suppressor gene have been reported in central nervous system (CNS), renal, and soft-tissue rhabdoid tumors. The present study was designed to compare the types of INI1 alterations among tumors from diverse anatomical sites and identify mutation hot spots. Fluorescence in situ hybridization and PCR-based microsatellite, heteroduplex, and sequence analysis were used to characterize chromosome 22 deletions and INI1 mutations among 100 primary rhabdoid tumors. Deletions and/or mutations of INI1 were detected in 75 patients, including 42 children with atypical teratoid/rhabdoid tumors of the brain or spinal cord and 6 children with a brain and a renal or soft-tissue tumor. Nineteen tumors arose in the kidney (in one child, bilaterally) and eight tumors were extra-renal. Homozygous deletions detected by fluorescence in situ hybridization were most often seen in CNS and extra-renal rhabdoid tumors, whereas truncating mutations were detected in a high percentage of CNS and kidney tumors. The highest frequencies of INI1 mutations for kidney tumors were seen in exons 2, 6, and 7, compared with exons 5 and 9 for CNS tumors. Two potential hot-spot mutations for CNS atypical teratoid/rhabdoid tumors were noted, including a C-to-T transition in codon 201 in exon 5 and a cytosine deletion in exon 9. Germ-line mutations were noted in 10 children, including 4 patients with two primary tumors. The majority of rhabdoid tumors from all sites contained deletions and/or mutations of the INI1 gene. Specific mutations were nonrandomly associated with anatomical site.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429635

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  103 in total

1.  BRG1 expression is increased in human glioma and controls glioma cell proliferation, migration and invasion in vitro.

Authors:  Jin Bai; Peng-Jin Mei; Hui Liu; Chen Li; Wang Li; Yong-Ping Wu; Zheng-Quan Yu; Jun-Nian Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-24       Impact factor: 4.553

2.  Study of the gene expression and microRNA expression profiles of malignant rhabdoid tumors originated in the brain (AT/RT) and in the kidney (RTK).

Authors:  Alex T Grupenmacher; Abby L Halpern; Maria de Fátima Bonaldo; Chiang-Ching Huang; Christopher A Hamm; Alexandre de Andrade; Tadanori Tomita; Simone T Sredni
Journal:  Childs Nerv Syst       Date:  2013-09-03       Impact factor: 1.475

3.  Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.

Authors:  Adam W Studebaker; Brian Hutzen; Christopher R Pierson; Terri A Shaffer; Corey Raffel; Eric M Jackson
Journal:  Neuro Oncol       Date:  2015-04-02       Impact factor: 12.300

4.  Atypical teratoid/rhabdoid tumor evolving from an optic pathway ganglioglioma: case study.

Authors:  Jeffrey C Allen; Alexander R Judkins; Marc K Rosenblum; Jaclyn A Biegel
Journal:  Neuro Oncol       Date:  2006-01       Impact factor: 12.300

Review 5.  Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies.

Authors:  Mandeep S Tamber; Krishan Bansal; Muh-Lii Liang; Todd G Mainprize; Bodour Salhia; Paul Northcott; Michael Taylor; James T Rutka
Journal:  Childs Nerv Syst       Date:  2006-09-02       Impact factor: 1.475

Review 6.  Molecular genetics of pediatric central nervous system tumors.

Authors:  Nicole J Ullrich; Scott L Pomeroy
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

7.  Multimodal treatments combined with gamma knife surgery for primary atypical teratoid/rhabdoid tumor of the central nervous system: a single-institute experience of 18 patients.

Authors:  Yan-Ming Ren; Xia Wu; Chao You; Yue-Kang Zhang; Qiang Li; Yan Ju
Journal:  Childs Nerv Syst       Date:  2017-12-07       Impact factor: 1.475

8.  Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes.

Authors:  Diane K Birks; Andrew M Donson; Purvi R Patel; Alexandra Sufit; Elizabeth M Algar; Christopher Dunham; B K Kleinschmidt-DeMasters; Michael H Handler; Rajeev Vibhakar; Nicholas K Foreman
Journal:  Pediatr Blood Cancer       Date:  2013-02-04       Impact factor: 3.167

Review 9.  Molecular analysis of pediatric brain tumors.

Authors:  Jaclyn A Biegel; Ian F Pollack
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

Review 10.  Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors.

Authors:  Sydney T Grob; Jean M Mulcahy Levy
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.